{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:07:01Z","timestamp":1790802421461,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117046","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:11:49Z","timestamp":1789139509000},"page":"117046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oncological impact of adjuvant chemotherapy after rectal cancer excision in the era of FOLFIRINOX-based TNT: A pooled post-hoc analysis of GRECCAR4-PRODIGE23"],"prefix":"10.1016","volume":"247","author":[{"given":"Quentin","family":"Denost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-3269","authenticated-orcid":false,"given":"Philippe","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-2913","authenticated-orcid":false,"given":"Bernard","family":"Lelong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Maingon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1785-6329","authenticated-orcid":false,"given":"Emmanuel","family":"Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Tuech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-3836","authenticated-orcid":false,"given":"Barbara","family":"Noiret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nougaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Pezzela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-284X","authenticated-orcid":false,"given":"Thierry","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ejca.2026.117046_bib1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.ejca.2026.117046_bib2","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1200\/JCO.19.00016","article-title":"Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117046_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant FOLFIRINOX and chemoradiotherapy versus chemoradiotherapy alone in locally advanced rectal cancer (PRODIGE 23): a multicentre, randomised, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117046_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/DCR.0000000000000849","article-title":"Tailored treatment strategy for locally advanced rectal carcinoma based on the tumor response to induction chemotherapy: preliminary results of the french phase II multicenter GRECCAR4 trial","volume":"60","author":"Rouanet","year":"2017","journal-title":"Dis Colon Rectum"},{"issue":"16","key":"10.1016\/j.ejca.2026.117046_bib5","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117046_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117046_bib7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdu560","article-title":"Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial","volume":"26","author":"Breugom","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117046_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117046_bib9","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.117046_bib10","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNAanalyses as markers of recurrence risk and benefit of adjuvant therapy for stage III coloncancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.117046_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1083285","article-title":"Circulating tumour DNA as biomarker for rectal cancer: a systematic review and meta-analyses","volume":"13","author":"Van Rees","year":"2023","journal-title":"Front Oncol"},{"issue":"10093","key":"10.1016\/j.ejca.2026.117046_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(17)31056-5","article-title":"Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial","volume":"390","author":"Rullier","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejca.2026.117046_bib13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S2468-1253(19)30410-8","article-title":"Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial","volume":"5","author":"Rullier","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.ejca.2026.117046_bib14","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA): a multi-center, randomized phase II trial","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"Jama 2022327(20)20222032 J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117046_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/codi.70009","article-title":"SELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma-free survival without major LARS following total mesorectal excision","volume":"27","author":"Ruteg\u00e5rd","year":"2025","journal-title":"Colorectal Dis"},{"issue":"3","key":"10.1016\/j.ejca.2026.117046_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/codi.16428","article-title":"A phase III randomized trial evaluating the quality of life impact of a tailored versus systematic use of defunctioning ileostomy following total mesorectal excision for rectal cancer-GRECCAR 17 trial protocol","volume":"25","author":"Denost","year":"2023","journal-title":"Colorectal Dis"},{"issue":"4","key":"10.1016\/j.ejca.2026.117046_bib17","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1245\/s10434-021-11197-2","article-title":"Tailored management with highly-selective diversion for low colorectal anastomosis: biochemical postoperative follow-up and long-term results from a single-institution cohort","volume":"29","author":"Rouanet","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117046_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.surg.2018.08.026","article-title":"Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy","volume":"165","author":"Huh","year":"2019","journal-title":"Surgery."},{"issue":"11","key":"10.1016\/j.ejca.2026.117046_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:09Z","timestamp":1790800389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":19,"alternative-id":["S0959804926008270"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117046","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological impact of adjuvant chemotherapy after rectal cancer excision in the era of FOLFIRINOX-based TNT: A pooled post-hoc analysis of GRECCAR4-PRODIGE23","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117046"}}